Hester Biosciences acquires technology from ICAR-NIHSAD to develop H9N2 strain vaccine for poultry

28 Dec 2022 Evaluate

Hester Biosciences has signed an agreement towards receiving indigenously developed technology from Indian Council of Agricultural Research - National Institute of High Security Animal Diseases (ICAR- NIHSAD), for the development and commercialization of the Low Pathogenic Avian Influenza (H9N2 strain) Inactivated Vaccine for poultry. The agreement was signed on December 27, 2022 at the office of Agrinnovate India, New Delhi. Agrinnovate is a government entity that acts as an interface between ICAR and the stakeholders in the agriculture sector, which includes technology transfers for vaccine manufacturing in the veterinary sector.

Besides supplying the vaccine within India, Hester intends to export this vaccine to African and Asian countries through Hester’s own distribution network, where the demand for this vaccine has already been established. The huge poultry population in India is a key source of livelihood for rural India. Until date, India had no vaccine available for Avian Influenza despite of periodic outbreaks across the country. These factors make this vaccine as having a significant commercial potential.

Hester Biosciences is engaged in the manufacturing of poultry vaccines.

Hester Biosciences Share Price

2377.75 -59.20 (-2.43%)
21-Nov-2024 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1777.65
Dr. Reddys Lab 1194.55
Cipla 1465.65
Lupin 2043.30
Zydus Lifesciences 944.25
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.